Impact of genetic notification on smoking cessation: Systematic review and pooled-analysis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  de Viron, Sylviane ^a,b,c   van der Heyden, Johan ^a   Ambrosino, Elena ^b   Arbyn, Marc ^a   Brand, Angela ^b,c   van Oyen, Herman ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANXIETY; DEPRESSION; FEMALE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC REGULATION; GENETIC RISK; HUMAN; MALE; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SYSTEMATIC REVIEW;

CONFIDENCE INTERVALS; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SMOKING; SMOKING CESSATION;

SCOPUS;

EID: 84863833761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040230     Document Type: Review

References (49)

1. CDC (2010) How Tobacco smoke causes disease: The Biology and behavioral basis for smoking-Attributale disease.
2. CDC (2008) Cigarette Smoking Among Adults - United States, 2007. MMWMR 57: 1221-1226.
3. Hughes JR, Keely J, Naud S, (2004) Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99: 29-38. 540 [pii].
4. Croyle RT, Lerman C, (1999) Risk communication in genetic testing for cancer susceptibility. J Natl Cancer Inst Monogr 59-66.
5. Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, et al. (2004) Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 13: 83-114. 480245 [pii];10.1023/B:JOGC.0000018821.48330.77 [doi].
6. Alexandrie AK, Nyberg F, Warholm M, Rannug A, (2004) Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev 13: 908-914. 13/6/908 [pii].
7. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O, (2004) Glutathione S-transferase T1 null-genotype is associated with an increased risk of lung cancer. Int J Cancer 110: 219-224. 10.1002/ijc.20075 [doi].
8. Shi X, Zhou S, Wang Z, Zhou Z, Wang Z, (2008) CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer 59: 155-163. S0169-5002(07)00440-0 [pii];10.1016/j.lungcan.2007.08.004 [doi].
9. Christensen PM, Gotzsche PC, Brosen K, (1997) The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 51: 389-393.
10. Spinola M, Falvella FS, Galvan A, Pignatiello C, Leoni VP, et al. (2007) Ethnic differences in frequencies of gene polymorphisms in the MYCL1 region and modulation of lung cancer patients' survival. Lung Cancer 55: 271-277. S0169-5002(06)00606-4 [pii];10.1016/j.lungcan.2006.10.023 [doi].
11. Sorensen K, Brand H, (2011) Health literacy: the essential catalyst for the responsible and effective translation of genome-based information for the benefit of population health. Public Health Genomics 14: 195-200. 000324241 [pii];10.1159/000324241 [doi].
12. Lipkus IM, (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making 27: 696-713. 0272989X07307271 [pii];10.1177/0272989X07307271 [doi].
13. Witte K, (1992) Putting the fear back into fear appeals: The extended parallel process model. Commun Monogr 59: 329-349.
14. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA, (2010) The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annual Review of Public Health 31: 89-103.
15. Haga SB, (2009) Ethical issues of predictive genetic testing for diabetes. J Diabetes Sci Technol 3: 781-788.
16. Manfredi C, Cho YI, Crittenden KS, Dolecek TA, (2007) A path model of smoking cessation in women smokers of low socio-economic status. Health Educ Res 22: 747-756. cyl155 [pii];10.1093/her/cyl155 [doi].
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
18. McBride CM, Bepler G, Lipkus IM, Lyna P, Samsa G, et al. (2002) Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiol Biomarkers Prev 11: 521-528.
19. Velicer WF, Prochaska JO, (2004) A comparison of four self-report smoking cessation outcome measures. Addict Behav 29: 51-60. S0306460303000844 [pii].
20. Audrain J, Boyd NR, Roth J, Main D, Caporaso NE, et al. (1997) Genetic susceptibility testing in smoking-cessation treatment: One-year outcomes of a randomized trial. Addictive Behaviors 22: 741-751.
21. Hishida A, Terazawa T, Mamiya T, Ito H, Matsuo K, et al. (2010) Efficacy of genotype notification to Japanese smokers on smoking cessation-An intervention study at workplace. Cancer Epidemiol 34: 96-100.
22. Ito H, Matsuo K, Wakai K, Saito T, Kumimoto H, et al. (2006) An intervention study of smoking cessation with feedback on genetic cancer susceptibility in Japan. Prev Med 42: 102-108. S0091-7435(05)00167-2 [pii];10.1016/j.ypmed.2005.10.006 [doi].
23. Lerman C, Gold K, Audrain J, Lin TH, Boyd NR, et al. (1997) Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. Health Psychol 16: 87-99.
24. Sanderson SC, Humphries SE, Hubbart C, Hughes E, Jarvis MJ, et al. (2008) Psychological and behavioural impact of genetic testing smokers for lung cancer risk: a phase II exploratory trial. J Health Psychol 13: 481-494. 13/4/481 [pii];10.1177/1359105308088519 [doi].
25. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, et al. (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20: 21-35. S0749379701002616 [pii].
26. Dersimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. 0197-2456(86)90046-2 [pii].
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. 10.1136/bmj.327.7414.557 [doi];327/7414/557 [pii].
28. Tobias A, (1999) sbe26: Assesing the influence of a single study in the meta-analysis estimate. Stata Techn Bull 47: 15-17.
29. Sanderson SC, Michie S, (2007) Genetic testing for heart disease susceptibility: potential impact on motivation to quit smoking. Clin Genet 71: 501-510. CGE810 [pii];10.1111/j.1399-0004.2007.00810.x [doi].
30. Sanderson SC, Wardle J, (2005) Will genetic testing for complex diseases increase motivation to quit smoking? Anticipated reactions in a survey of smokers. Health Educ Behav 32: 640-653. 32/5/640 [pii];10.1177/1090198105278756 [doi].
31. Westmaas JL, Woicik PB, (2005) Dispositional motivations and genetic risk feedback. Addict Behav 30: 1524-1534. S0306-4603(05)00056-0 [pii];10.1016/j.addbeh.2005.03.002 [doi].
32. Wright AJ, French DP, Weinman J, Marteau TM, (2006) Can genetic risk information enhance motivation for smoking cessation? An analogue study. Health Psychol 25: 740-752. 2006-20659-009 [pii];10.1037/0278-6133.25.6.740 [doi].
33. Wright AJ, Aveyard P, Guo B, Murphy M, Brown K, et al. (2007) Is attributing smoking to genetic causes associated with a reduced probability of quit attempt success? A cohort study. Addiction 102: 1657-1664. ADD1937 [pii];10.1111/j.1360-0443.2007.01937.x [doi].
34. Wright AJ, Takeichi C, Whitwell SC, Hankins M, Marteau TM, (2008) The impact of genetic testing for Crohn's disease, risk magnitude and graphical format on motivation to stop smoking: an experimental analogue study. Clin Genet 73: 306-314. CGE964 [pii];10.1111/j.1399-0004.2008.00964.x [doi].
35. Wright AJ, Weinman J, Marteau TM, (2003) The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tob Control 12: 227-230.
36. Carpenter MJ, Strange C, Jones Y, Dickson MR, Carter C, et al. (2007) Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med 33: 22-28. 10.1207/s15324796abm3301_3 [doi].
37. Lipkus IM, McBride CM, Pollak KI, Lyna P, Bepler G, (2004) Interpretation of genetic risk feedback among African American smokers with low socioeconomic status. Health Psychol 23: 178-188. 10.1037/0278-6133.23.2.178 [doi];2004-11615-011 [pii].
38. Sanderson SC, O'Neill SC, White DB, Bepler G, Bastian L, et al. (2009) Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev 18: 1953-1961. 1055-9965.EPI-08-0620 [pii];10.1158/1055-9965.EPI-08-0620 [doi].
39. Uhl GR, Drgon T, Johnson C, Rose JE, (2009) Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials. Pharmacogenomics J 9: 111-115. tpj200810 [pii];10.1038/tpj.2008.10 [doi].
40. Hamajima N, Atsuta Y, Goto Y, Ito H, (2004) A pilot study on genotype announcement to induce smoking cessation by Japanese smokers. Asian Pac J Cancer Prev 5: 409-413.
41. Kano M, Goto Y, Atsuta Y, Naito M, Hamajima N, (2007) Smoking cessation after genotype notification: pilot studies of smokers employed by a municipal government and those on Nagoya University medical campus. Nagoya J Med Sci 69: 149-156.
42. Sanderson SC, Wardle J, Humphries SE, (2008) Public health genomics and genetic test evaluation: the challenge of conducting behavioural research on the utility of lifestyle-genetic tests. J Nutrigenet Nutrigenomics 1: 224-231. 000149826 [pii];10.1159/000149826 [doi].
43. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, et al. (2008) Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 17: 2834-2848. ddn181 [pii];10.1093/hmg/ddn181 [doi].
44. Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, et al. (2004) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4: 184-192. 10.1038/sj.tpj.6500238 [doi];6500238 [pii].
45. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, et al. (2006) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31: 231-242. 1300861 [pii];10.1038/sj.npp.1300861 [doi].
46. Smerecnik C, Grispen JE, Quaak M, (2011) Effectiveness of testing for genetic susceptibility to smoking-related diseases on smoking cessation outcomes: a systematic review and meta-analysis. Tob Control. tc.2011.042739 [pii];10.1136/tc.2011.042739 [doi].
47. Carlsten C, Halperin A, Crouch J, Burke W, (2011) Personalized medicine and tobacco-related health disparities: is there a role for genetics? Ann Fam Med 9: 366-371. 9/4/366 [pii];10.1370/afm.1244 [doi].
48. Prochaska JO, Diclemente CC, (1983) Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51: 390-395.
49. Munafo MR, Clark TG, Flint J, (2004) Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129: 39-44. S0165178104001684 [pii];10.1016/j.psychres.2004.06.011 [doi].